Developer docs
API playgroundTry for free, no card

Search company profiles

AriBio

Full company profile

uuid0000v7p

Namestring
AriBio
Legal namestring
AriBio Co., Ltd.
Websiteurl
aribio.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

AriBio Co., Ltd. is a clinical-stage biopharmaceutical company founded in 2010 in Seongnam-si, South Korea, developing therapeutics for neurodegenerative and infectious diseases. Its lead asset, AR1001 (mirodenafil), is a once-daily oral second-generation phosphodiesterase-5 (PDE5) inhibitor designed to deliver disease-modifying treatment for early Alzheimer's disease (mild cognitive impairment to mild dementia). The drug exerts polypharmacological effects including neuroprotection, inhibition of tau phosphorylation, suppression of inflammatory responses, and improvement of cerebral blood flow, with demonstrated blood-brain barrier penetration and substantially lower ARIA risk versus approved antibody therapies. AR1001 is currently in the global Phase 3 POLARIS-AD trial, which has completed enrollment of 1,535 patients across approximately 230 clinical centers in 13 countries, supported by IND/CTA approvals from FDA, EMA, MHRA, NMPA, and MFDS. Drug discovery is conducted through the company's proprietary ARIDD™ (AI-powered, Reverse engineered & Integrated Drug Development) platform, which was further integrated with Eli Lilly's Lilly TuneLab AI platform in June 2026.

AriBio operates an asset-light, partnership-driven commercial model. The company retains global development control of AR1001 while licensing regional and global commercialization rights to pharmaceutical partners who fund manufacturing, regulatory, and sales activities in their territories. Current licensees include Fosun Pharma (global — U.S., Europe, Japan, ASEAN, Greater China, with cumulative deal value approaching $4.7 billion), Arcera/Acino (Latin America, Middle East, Southern Africa, Ukraine, Eurasia — $600M deal value), Neuco United (Greater China channel), Samjin Pharmaceutical (South Korea — ~$77M), and RESTARI (polycystic kidney disease and cystic liver diseases — $400M+ potential). Revenue mechanics consist of upfront option fees (e.g., $60M from Fosun in May 2026), milestone payments tied to regulatory and sales achievements, and tiered double-digit royalties on net sales in partner territories.

The company is privately held with no parent entity and 51-100 employees. Co-founders Jai Jun Choung (Chairman and Co-CEO, leading R&D and clinical development) and Soo Hyun Sung (Co-CEO, leading business strategy and fundraising) maintain central leadership. KOSDAQ-listed Solux holds a 15.03% stake following staged investments and is the planned merger counterparty for a KOSDAQ listing transaction targeted for July 10, 2026. Operations are conducted from headquarters in Bundang-gu, Seongnam-si, South Korea and a U.S. office in San Diego, California supporting global clinical development, CMC, and regulatory affairs.

Short descriptiontext

AriBio is a clinical-stage South Korean biopharmaceutical company developing AR1001, an oral PDE5 inhibitor for early Alzheimer's disease currently in global Phase 3 trials. The company licenses commercialization rights to global pharma partners and is pursuing a KOSDAQ listing via merger with Solux.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, clinical-stage biopharmaceutical, Alzheimer's disease treatment, PDE5 inhibitor drug development, AI-powered drug discovery
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceuticals — Neurodegenerative Disease Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Global Licensing and Milestone Payments
TypeLicensing Royalties
Description

AriBio generates revenue through upfront option fees, milestone payments upon regulatory achievements (IND approvals, trial completions, regulatory approvals), and tiered double-digit royalties on net sales of licensed products in partner territories. The Fosun Pharma deal includes $60M option fee, $80M upon option exercise, plus milestone payments and royalties.

aribio.com
2R&D Investment Funding
TypeLicensing Royalties
Description

The company raises investment capital from financial partners (Solux) to fund research and development costs for clinical trials and drug development programs, including Phase 3 trials for AR1001.

dailypharm.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AriBio is a clinical-stage biopharmaceutical company developing AR1001 (mirodenafil), a once-daily oral phosphodiesterase-5 (PDE5) inhibitor with disease-modifying potential for early Alzheimer's disease, currently in a global Phase 3 POLARIS-AD trial. The company also operates the ARIDD AI-powered drug discovery platform, and markets ancillary wellness products (Herzion transcranial vibroacoustic stimulation device, TeloAct hair-loss solution) leveraging its neurodegeneration research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 69% reduced risk of developing Alzheimer's dementia in sildenafil users (Cleveland Clinic study, Nature Aging)
+4 more records
Product overview1 text field

AriBio Co., Ltd. is a clinical-stage biopharmaceutical company developing neurodegenerative disease therapies. The core product is AR1001 (mirodenafil), a best-in-class once-daily oral PDE5 inhibitor in Phase 3 trials for early Alzheimer's disease, being positioned as the first oral disease-modifying treatment for the condition. The company's ARIDD (AI-powered, Reverse engineered & Integrated Drug Development) platform supports its drug discovery pipeline. AriBio has also developed wellness products including Herzion, a transcranial vibroacoustic stimulation device, and TeloAct, a hair-loss solution, leveraging research in neurodegenerative brain disorders. Strategic licensing partnerships have been established with Fosun Pharma (global), Arcera (Latin America, Middle East), Neuco United/Fosun (China), and RESTARI (polycystic kidney disease, cystic liver diseases).

Product and service3 records
1AR1001 (Mirodenafil)
CategoryCore Product — Alzheimer's Disease Therapeutic
Description

Best-in-class once-daily oral phosphodiesterase-5 (PDE5) inhibitor candidate intended for the treatment of early Alzheimer's disease (mild cognitive impairment to mild dementia). Demonstrates multiple mechanisms including neuroprotection, inhibition of tau phosphorylation, suppression of inflammatory responses, and improvement of cerebral blood flow; favorable safety profile with substantially lower ARIA risk than antibody therapies. Currently in global Phase 3 trial with over 1,500 patients enrolled across 13 countries; commercialized via regional and global licensing partners (Fosun Pharma, Arcera, Neuco United, Samjin Pharmaceutical).

2Herzion
CategoryWellness / Consumer Health Device
Description

Transcranial vibroacoustic stimulation device developed from AriBio's neurodegenerative brain disorder research, marketed as a wellness product.

3TeloAct
CategoryWellness / Consumer Health Product
Description

Hair-loss solution product developed and marketed by AriBio.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-05
Description

AriBio joined Lilly TuneLab, an AI-powered drug discovery platform developed by Eli Lilly. The collaboration provides access to AI and machine learning models trained on decades of Eli Lilly research data to support neuroscience drug development. AriBio integrates Lilly TuneLab with its existing ARIDD platform to improve data-driven decision-making and efficiency in developing therapies for neurodegenerative diseases. The company also separately stated it is pursuing a merger with Solux as part of its strategy to expand its biotechnology platform business.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-13
Description

Exclusive global option agreement for AR1001, an oral PDE5 inhibitor for Alzheimer's disease, extending prior regional partnership to worldwide markets (U.S., Europe, Japan). Fosun Pharma pays $60M option fee upfront, with potential additional payments of up to $180M in milestone payments and further sales milestones tied to $2.5B in annual net sales. Total deal value up to $4.7 billion. Fosun handles R&D, manufacturing, regulatory affairs, and commercialization globally. Topline Phase 3 results expected 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

Exclusive license and commercialization agreement for a small molecule targeting polycystic kidney disease (PKD) and cystic liver diseases (CLD). RESTARI receives exclusive rights outside AriBio's retained territories. Collaboration leverages AriBio's PDE5 inhibitor pre-clinical and clinical development expertise. Transaction includes development, regulatory, and commercial milestone payments plus royalties, with total potential lifetime deal value exceeding $400 million. A letter of intent for co-development of kidney and liver disease therapeutics was signed May 8, 2025.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-01-07
Description

Exclusive licensing agreement for AR1001 across 10 ASEAN countries (Singapore, Indonesia, Philippines, Thailand, Vietnam, Cambodia, Laos, Malaysia, Myanmar, Brunei) valued at approximately 630 billion KRW (~$424 million USD). Fosun Pharma handles manufacturing, regulatory licensing, and commercialization in these markets. Cumulative value of global exclusive rights contracts for AR1001 reaches approximately 2.99 trillion KRW.

5Neuco United
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-07-28
Description

Neuco United holds exclusive rights to AR1001 for Greater China (Chinese mainland, Hong Kong SAR, Macau SAR). Arranged licensing agreement with Fosun Pharma for manufacturing and commercialization in Greater China. Neuco United coordinates with AriBio on the ongoing global Phase 3 clinical trial. Three parties to enter technology transfer and supply agreement for commercial readiness in China.

aribio.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-06-10
Description

Exclusive licensing and supply agreements for AR1001 covering Latin America, the Middle East, Southern Africa, Ukraine, and select Eurasian countries. Total deal value estimated at $600 million USD across development, launch, and commercialization period contingent on milestone achievements. Arcera commercializes the product while AriBio manufactures and supplies. Facilitated by KDB Industrial Bank's Global Partnership Support Program.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-23
Description

Strategic partnership for biomarker development for Alzheimer's disease and neurodegeneration. AriBio provides plasma and matched CSF samples from the ongoing Phase 3 POLARIS-AD trial. Fujirebio gains access to clinical samples and data, supporting their Lumipulse® platform biomarker development and blood-based diagnostic assays. The partnership fulfilled AriBio's commitment to provide over 1,150 plasma and matched CSF sample sets. Samples continue to be collected for an additional year as part of the extension phase.

Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2024-06-21
Description

Strategic collaboration for testing of cerebral spinal fluid (CSF) to aid in Alzheimer's disease diagnosis using the Lumipulse® system. KCTL provides improved access and efficient testing capabilities utilizing both CSF and plasma samples in FDA and EMA approved assays. Supports POLARIS-AD study across North America, EU, UK, and Korea.

9Samjin Pharmaceutical
Strategic tierSecondaryTypeGTM or Marketing PartnerAnnounced on2024-03-24
Description

Exclusive marketing rights agreement for AR1001 for Alzheimer's disease in South Korea. Deal valued at 100 billion KRW (~USD 77 million). Samjin Pharmaceutical handles commercialization in the Korean market.

aribio.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Original exclusive licensing agreement for AR1001 manufacturing and commercialization in Chinese mainland, Hong Kong, and Macau. Deal executed through Neuco United. Fosun Pharma now expanding to broader ASEAN markets following initial Greater China agreement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership leveraging AriBio's phosphodiesterase 5 (PDE5) inhibitor technology to co-develop new therapeutics for cystic kidney diseases (including polycystic kidney disease) and chronic liver disease. The collaboration combines drug discovery platforms and expertise from both companies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AriBio

Biopharmaceuticals — Neurodegenerative Disease Therapeuticsaribio.com

AriBio is a clinical-stage South Korean biopharmaceutical company developing AR1001, an oral PDE5 inhibitor for early Alzheimer's disease currently in global Phase 3 trials. The company licenses commercialization rights to global pharma partners and is pursuing a KOSDAQ listing via merger with Solux.

What AriBio does

AriBio Co., Ltd. is a clinical-stage biopharmaceutical company founded in 2010 in Seongnam-si, South Korea, developing therapeutics for neurodegenerative and infectious diseases. Its lead asset, AR1001 (mirodenafil), is a once-daily oral second-generation phosphodiesterase-5 (PDE5) inhibitor designed to deliver disease-modifying treatment for early Alzheimer's disease (mild cognitive impairment to mild dementia). The drug exerts polypharmacological effects including neuroprotection, inhibition of tau phosphorylation, suppression of inflammatory responses, and improvement of cerebral blood flow, with demonstrated blood-brain barrier penetration and substantially lower ARIA risk versus approved antibody therapies. AR1001 is currently in the global Phase 3 POLARIS-AD trial, which has completed enrollment of 1,535 patients across approximately 230 clinical centers in 13 countries, supported by IND/CTA approvals from FDA, EMA, MHRA, NMPA, and MFDS. Drug discovery is conducted through the company's proprietary ARIDD™ (AI-powered, Reverse engineered & Integrated Drug Development) platform, which was further integrated with Eli Lilly's Lilly TuneLab AI platform in June 2026.

AriBio operates an asset-light, partnership-driven commercial model. The company retains global development control of AR1001 while licensing regional and global commercialization rights to pharmaceutical partners who fund manufacturing, regulatory, and sales activities in their territories. Current licensees include Fosun Pharma (global — U.S., Europe, Japan, ASEAN, Greater China, with cumulative deal value approaching $4.7 billion), Arcera/Acino (Latin America, Middle East, Southern Africa, Ukraine, Eurasia — $600M deal value), Neuco United (Greater China channel), Samjin Pharmaceutical (South Korea — ~$77M), and RESTARI (polycystic kidney disease and cystic liver diseases — $400M+ potential). Revenue mechanics consist of upfront option fees (e.g., $60M from Fosun in May 2026), milestone payments tied to regulatory and sales achievements, and tiered double-digit royalties on net sales in partner territories.

The company is privately held with no parent entity and 51-100 employees. Co-founders Jai Jun Choung (Chairman and Co-CEO, leading R&D and clinical development) and Soo Hyun Sung (Co-CEO, leading business strategy and fundraising) maintain central leadership. KOSDAQ-listed Solux holds a 15.03% stake following staged investments and is the planned merger counterparty for a KOSDAQ listing transaction targeted for July 10, 2026. Operations are conducted from headquarters in Bundang-gu, Seongnam-si, South Korea and a U.S. office in San Diego, California supporting global clinical development, CMC, and regulatory affairs.

AriBio firmographics

Firmographics
Name
AriBio
Legal name
AriBio Co., Ltd.
Website
https://aribio.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
AriBio is a clinical-stage South Korean biopharmaceutical company developing AR1001, an oral PDE5 inhibitor for early Alzheimer's disease currently in global Phase 3 trials. The company licenses commercialization rights to global pharma partners and is pursuing a KOSDAQ listing via merger with Solux.
Ownership category
akta.pro rank

AriBio industry classification

Industry
Product category
Biopharmaceuticals — Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • Clinical-stage biopharmaceutical
  • Alzheimer's disease treatment
  • PDE5 inhibitor drug development
  • AI-powered drug discovery

Where AriBio is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

AriBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Global Licensing and Milestone Payments: AriBio generates revenue through upfront option fees, milestone payments upon regulatory achievements (IND approvals, trial completions, regulatory approvals), and tiered double-digit royalties on net sales of licensed products in partner territories. The Fosun Pharma deal includes $60M option fee, $80M upon option exercise, plus milestone payments and royalties.
  2. R&D Investment Funding: The company raises investment capital from financial partners (Solux) to fund research and development costs for clinical trials and drug development programs, including Phase 3 trials for AR1001.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

AriBio product offering

Product offering

Core offering

AriBio is a clinical-stage biopharmaceutical company developing AR1001 (mirodenafil), a once-daily oral phosphodiesterase-5 (PDE5) inhibitor with disease-modifying potential for early Alzheimer's disease, currently in a global Phase 3 POLARIS-AD trial. The company also operates the ARIDD AI-powered drug discovery platform, and markets ancillary wellness products (Herzion transcranial vibroacoustic stimulation device, TeloAct hair-loss solution) leveraging its neurodegeneration research.

Product overview

AriBio Co., Ltd. is a clinical-stage biopharmaceutical company developing neurodegenerative disease therapies. The core product is AR1001 (mirodenafil), a best-in-class once-daily oral PDE5 inhibitor in Phase 3 trials for early Alzheimer's disease, being positioned as the first oral disease-modifying treatment for the condition. The company's ARIDD (AI-powered, Reverse engineered & Integrated Drug Development) platform supports its drug discovery pipeline. AriBio has also developed wellness products including Herzion, a transcranial vibroacoustic stimulation device, and TeloAct, a hair-loss solution, leveraging research in neurodegenerative brain disorders. Strategic licensing partnerships have been established with Fosun Pharma (global), Arcera (Latin America, Middle East), Neuco United/Fosun (China), and RESTARI (polycystic kidney disease, cystic liver diseases).

Differentiator

Problem solved

Functional benefit

Products and services

  • AR1001 (Mirodenafil) Best-in-class once-daily oral phosphodiesterase-5 (PDE5) inhibitor candidate intended for the treatment of early Alzheimer's disease (mild cognitive impairment to mild dementia). Demonstrates multiple mechanisms including neuroprotection, inhibition of tau phosphorylation, suppression of inflammatory responses, and improvement of cerebral blood flow; favorable safety profile with substantially lower ARIA risk than antibody therapies. Currently in global Phase 3 trial with over 1,500 patients enrolled across 13 countries; commercialized via regional and global licensing partners (Fosun Pharma, Arcera, Neuco United, Samjin Pharmaceutical).
  • Herzion Transcranial vibroacoustic stimulation device developed from AriBio's neurodegenerative brain disorder research, marketed as a wellness product.
  • TeloAct Hair-loss solution product developed and marketed by AriBio.

Quantifiable outcome

  • 69% reduced risk of developing Alzheimer's dementia in sildenafil users (Cleveland Clinic study, Nature Aging)
  • +4 more outcomes

Companies that use AriBio

Customer profile

Segments1 record

Ideal customer profiles3 records

AriBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

AriBio partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and secondary.

  • Eli Lilly (Lilly TuneLab)coreTechnology or Integration · 5 June 2026AriBio joined Lilly TuneLab, an AI-powered drug discovery platform developed by Eli Lilly. The collaboration provides access to AI and machine learning models trained on decades of Eli Lilly research data to support neuroscience drug development. AriBio integrates Lilly TuneLab with its existing ARIDD platform to improve data-driven decision-making and efficiency in developing therapies for neurodegenerative diseases. The company also separately stated it is pursuing a merger with Solux as part of its strategy to expand its biotechnology platform business.
  • Fosun PharmacoreGTM or Marketing Partner · 13 May 2026Exclusive global option agreement for AR1001, an oral PDE5 inhibitor for Alzheimer's disease, extending prior regional partnership to worldwide markets (U.S., Europe, Japan). Fosun Pharma pays $60M option fee upfront, with potential additional payments of up to $180M in milestone payments and further sales milestones tied to $2.5B in annual net sales. Total deal value up to $4.7 billion. Fosun handles R&D, manufacturing, regulatory affairs, and commercialization globally. Topline Phase 3 results expected 2026.
  • RESTARIcoreStrategic or Co-development Partner · 4 February 2026Exclusive license and commercialization agreement for a small molecule targeting polycystic kidney disease (PKD) and cystic liver diseases (CLD). RESTARI receives exclusive rights outside AriBio's retained territories. Collaboration leverages AriBio's PDE5 inhibitor pre-clinical and clinical development expertise. Transaction includes development, regulatory, and commercial milestone payments plus royalties, with total potential lifetime deal value exceeding $400 million. A letter of intent for co-development of kidney and liver disease therapeutics was signed May 8, 2025.
  • Fosun Pharma (ASEAN)coreGTM or Marketing Partner · 7 January 2026Exclusive licensing agreement for AR1001 across 10 ASEAN countries (Singapore, Indonesia, Philippines, Thailand, Vietnam, Cambodia, Laos, Malaysia, Myanmar, Brunei) valued at approximately 630 billion KRW (~$424 million USD). Fosun Pharma handles manufacturing, regulatory licensing, and commercialization in these markets. Cumulative value of global exclusive rights contracts for AR1001 reaches approximately 2.99 trillion KRW.
  • Neuco UnitedcoreGTM or Marketing Partner · 28 July 2025Neuco United holds exclusive rights to AR1001 for Greater China (Chinese mainland, Hong Kong SAR, Macau SAR). Arranged licensing agreement with Fosun Pharma for manufacturing and commercialization in Greater China. Neuco United coordinates with AriBio on the ongoing global Phase 3 clinical trial. Three parties to enter technology transfer and supply agreement for commercial readiness in China.
  • Arcera (Acino)coreGTM or Marketing Partner · 10 June 2025Exclusive licensing and supply agreements for AR1001 covering Latin America, the Middle East, Southern Africa, Ukraine, and select Eurasian countries. Total deal value estimated at $600 million USD across development, launch, and commercialization period contingent on milestone achievements. Arcera commercializes the product while AriBio manufactures and supplies. Facilitated by KDB Industrial Bank's Global Partnership Support Program.
  • Fujirebio DiagnosticscoreTechnology or Integration · 23 April 2025Strategic partnership for biomarker development for Alzheimer's disease and neurodegeneration. AriBio provides plasma and matched CSF samples from the ongoing Phase 3 POLARIS-AD trial. Fujirebio gains access to clinical samples and data, supporting their Lumipulse® platform biomarker development and blood-based diagnostic assays. The partnership fulfilled AriBio's commitment to provide over 1,150 plasma and matched CSF sample sets. Samples continue to be collected for an additional year as part of the extension phase.
  • Kentucky Clinical Trial Laboratory (KCTL)secondaryTechnology or Integration · 21 June 2024Strategic collaboration for testing of cerebral spinal fluid (CSF) to aid in Alzheimer's disease diagnosis using the Lumipulse® system. KCTL provides improved access and efficient testing capabilities utilizing both CSF and plasma samples in FDA and EMA approved assays. Supports POLARIS-AD study across North America, EU, UK, and Korea.
  • Samjin PharmaceuticalsecondaryGTM or Marketing Partner · 24 March 2024Exclusive marketing rights agreement for AR1001 for Alzheimer's disease in South Korea. Deal valued at 100 billion KRW (~USD 77 million). Samjin Pharmaceutical handles commercialization in the Korean market.
  • Fosun Pharma (China)coreGTM or Marketing PartnerOriginal exclusive licensing agreement for AR1001 manufacturing and commercialization in Chinese mainland, Hong Kong, and Macau. Deal executed through Neuco United. Fosun Pharma now expanding to broader ASEAN markets following initial Greater China agreement.
  • RESTARI (Co-development)coreStrategic or Co-development PartnerPartnership leveraging AriBio's phosphodiesterase 5 (PDE5) inhibitor technology to co-develop new therapeutics for cystic kidney diseases (including polycystic kidney disease) and chronic liver disease. The collaboration combines drug discovery platforms and expertise from both companies.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

AriBio competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

AriBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AriBio leadership team

Management profile

Number of profiles

Profiles6 records

AriBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AriBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AriBio

What does AriBio do?

AriBio is a clinical-stage biopharmaceutical company developing AR1001 (mirodenafil), a once-daily oral phosphodiesterase-5 (PDE5) inhibitor with disease-modifying potential for early Alzheimer's disease, currently in a global Phase 3 POLARIS-AD trial. The company also operates the ARIDD AI-powered drug discovery platform, and markets ancillary wellness products (Herzion transcranial vibroacoustic stimulation device, TeloAct hair-loss solution) leveraging its neurodegeneration research.

Is AriBio a public or private company?

AriBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was AriBio founded?

AriBio was founded in 2010. It employs 11 to 50 people.

Where is AriBio based?

AriBio is headquartered in Seongnam, South Korea, in the Asia region.

How does AriBio make money?

Two revenue lines are on record. Global Licensing and Milestone Payments are the primary driver. The others are R&D Investment Funding.

Does AriBio have an API?

No public API is recorded for AriBio.

What industry is AriBio in?

AriBio's product category is Biopharmaceuticals — Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
New York PostAn erectile disfunction drug could be the next Alzheimer’s treatmentA new drug AR1001, based on the Korean ED drug mirodenafil, showed 31% slower cognitive decline in a subset of Alzheimer's patients in a phase 3 trial. AriBio plans to seek FDA approval in 2027, potentially making it the first oral treatment for the disease.Inc.A Pill for Erectile Dysfunction Slowed Alzheimer’s Decline by 31 Percent. That Wasn’t the Full StoryAriBio's erectile dysfunction drug AR1001 slowed Alzheimer's decline by 31 percent in a subset of patients not taking other dementia drugs, according to a Phase 3 trial presented at CTAD. The trial enrolled 1,535 participants across 13 countries, with the result applying only to 604 participants.Gadgets 360Drug That Mimics Viagra Slows Down Alzheimer's Progression, Offers HopeA drug called AR1001, developed by AriBio, is being tested for Alzheimer's and has been likened to Viagra. In a trial across 13 countries, it slowed cognitive decline by nearly a third in 604 patients not taking other drugs. The company is conducting further research before public approval.The Pharma LetterAriBio’s Alzheimer’s pill slows decline in monotherapy groupAriBio's AR1001 slowed clinical decline by 31% versus placebo in a prespecified monotherapy group of 604 early Alzheimer's patients. Across the full Phase III trial of 1,535 participants, the drug-placebo difference fell short of statistical significance. The monotherapy result met the primary efficacy objective.YahooThe first pill to slow Alzheimer’s could come from an unexpected placeAriBio's Mvix, a Viagra-like pill, slowed mental decline in a year-long trial of over 1,500 early Alzheimer's patients, but only in those not taking other dementia drugs. The low-dose version reduced decline by nearly a third compared to placebo, and the company plans to discuss FDA approval.BioSpaceCTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapyAriBio reported at CTAD 2026 that its Alzheimer's drug AR1001 slowed cognitive decline by 31% versus placebo in a Phase 3 trial of patients not on other Alzheimer's medicines. The monotherapy result met one of two primary endpoints, while the overall population showed a non-significant 7% slowing. The company plans to discuss results with the FDA.The IndependentNew Viagra-like drug could slow down decline of Alzheimer’sA new drug AR1001, a phosphodiesterase-5 inhibitor, reduced cognitive decline by 31% in early-stage Alzheimer's patients in a trial of 604 people. The drug, developed by AriBio, was ineffective in patients already on other Alzheimer's medications. It is not yet available and requires regulatory approval.NaverAriBio's Alzheimer's pill fails to deliver benefits to Phase 3 full trial populationAriBio's experimental Alzheimer's drug AR1001 slowed disease progression by 31 percent in 604 patients not on existing dementia treatments, but failed to show a statistically significant benefit across the full Phase 3 trial population of 1,535 patients. The drug did not improve secondary cognitive measures, and serious adverse effects occurred in about 10 percent of patients.NateAriBio Lab, Soar…HLB Therapeutics Hits Lower Limit[K-Bio Bulse] : 네이트 뉴스AriBio Lab rose 27% ahead of its Alzheimer's drug AR1001 Phase 3 results, while Corestem ChemOn hit the upper limit after FDA minutes clarified its ALS therapy path, and HLB Therapeutics fell 30% after a US Phase 3 failure. The results will be presented at CTAD 2026 in Boston.